Scale Modeling of Medical Molecular Systems
Human body is mainly made by several biomacromolecules. The mal-function of proteins and nucleic acids set up our diseases; it would be considered that ca. 70% of human diseases occurred by that of receptor proteins, especially. Therefore the clarification of relationship between structure and function on bio-macromolecule is one of the highest priorities in the pharmaceutical science field. Nowadays, several technical innovations on structural biology (sample expression by genetic technology, innovation of measurements; i.e. SOR (Synchrotron Orbit Radiation) or giant NMR (Nuclear Magnetic Resonance) and so on, structural analysis calculation by super computer) make easy to analyze stereo structure of macromolecules. However, number of determined structures would not clear up the relationship between structure and function on biomacromolecules systematically.
On the other hand, the author found the molecular model on biomacromolecule resembles a “space truss structure” in the Building Engineeringtectonics or a “space link” in the Mechanics. Therefore the molecular model must be obeyed by the rules on these Kinematics at least, and a real molecule may be obeyed also. The simplest principle, the balance of internal degree of freedom and number of restraints in the molecule, would be determined the molecular stiffness or flexibility or mechanism. DNA and some protein structures will be discussed under the principle.
KeywordsMedical molecular system degree of freedom protein nucleic acid enzyme receptor
Unable to display preview. Download preview PDF.
- 1.Watson, J. D., Crick, F. H. C. “Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid”. Nature, 4356 April 25, (1953).Google Scholar
- 2.Matsumoto O., Taga T., Matsushima M., Higashi T., Machida K. “Multiple binding of inhibitors in the complex formed by bovine trypsin and fragments of a synthetic inhibitor, 4-[4-(N,N-dimethylcarbamoxylmethoxycarbonylmethyl)phenoxycarbonylphenyl]guanidinium methanesulfonate (FOY-305)”. Chem Pharm Bull (Tokyo). 38:2253–5. (1990).Google Scholar
- 3.Matsumoto, O., Taga T., Higashi T., Matsushima M., Machida K. “Complex formation by bovine trypsin and a tetrapeptide (Leu-Arg-Pro-Gly-NH2): X-ray structure analysis of the complex in the orthorhombic crystal form with low molecular packing density”. J. Protein Chem. 5: 589–93 (1990).CrossRefGoogle Scholar
- 4.Vassylyev, D., G. Katayanagi, K. Ishikawa, K. Tsujimoto-Hirano, M. Danno, M. Pahler, A., Matsumoto, O., Matsushima, M., Yoshida, H., Morikawa, K. “Crystal structures of ribonuclease F1 of Fusarium moniliforme in its free form and in complex with 2’GMP”. J. Mol. Biol. 230: 979–96 (1993).CrossRefGoogle Scholar
- 6.Morikawa K., Ariyoshi M., Vassylyev D.G., Matsumoto O., Katayanagi K., Ohtsuka E. “Crystal structure of a pyrimidine dimer-specific excision repair enzyme from bacteriophage T4: Refinement at 1.45 A and X-ray analysis of the three active site mutants”., J. Mol. Biol. 249: 360–75 (1995).CrossRefGoogle Scholar
- 8.Dickerson, R. E., Geis, I. The Structure and Action of Proteins, Harper & Row, New York, 1969.Google Scholar
- 9.Watson, J. D. The Double Helix, Atheneum, New York, 1967.Google Scholar
- 10.Drew, H. R., Dickerson, R. E. “Structure of a DNA dodecamer. III. Geometry of hydration”. J. Mol. Biol. 55: 379–400 (1981).Google Scholar
- 13.Sakurai, F., Inoue, R., Nishino, Y., Okuda, A., Matsumoto, O., Taga, T., Yamashita, F., Takakura, Y., Hashida, M. “Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression”. J Control Release. 66: 255–69 (2000)CrossRefGoogle Scholar
- 14.Sakurai, F., Nishioka, T., Saito, H., Baba, T., Okuda, A., Matsumoto, O., Taga, T., Yamashita, F., Takakura, Y., Hashida, M. “Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid”. Gene Ther. 6: 677–86. (2001).CrossRefGoogle Scholar
- 21.Ichikawa, A., Negishi, M., Hasegawa, H. “Three isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive Gi activity and agonist-dependent Gs activity”. Adv Exp Med Biol. 433: 239–42 (1997).Google Scholar
- 23.Lambright, D. G., Noel, J. P., Hamm, H. E., Siegler, P. B. “Structural determinants for activation of the alpha-subunit of a heterotrimeric G protein”. Nature 369: 621–8 (1994).Google Scholar
- 24.Hangai, Y., Kawaguchi, K. “Keitai Kaiseki”. Baifukan, Tokyo, 1991, p. 67 (in Japanese).Google Scholar
- 26.Takeuchi, Y., Nonaka, T., Nakamura, K. T., Kojima, S., Miura, K.-I., Mitsui, Y. “Crystal structure of an engineered subtilisin inhibitor complexed with bovine trypsin”. Proc. Natl. Acad. Sci. USA 89: 4407–11 (1992).Google Scholar
- 27.Matsumoto, O., Taga, T., Higashi, T., Matsushima, M., Machida, K. “Complex formation by bovine trypsin and a tetrapeptide (Leu-Arg-Pro-Gly-NH2): X-ray structure analysis of the complex in the orthorhombic crystal form with low molecular packing density”. J. Protein Chem. 9: 589–593 (1990).CrossRefGoogle Scholar